BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Carrasquillo OY, Pabón-cartagena G, Falto-aizpurua LA, Santiago-vázquez M, Cancel-artau KJ, Arias-berrios G, Martín-garcía RF. Treatment of erythrodermic psoriasis with biologics: A systematic review. Journal of the American Academy of Dermatology 2020;83:151-8. [DOI: 10.1016/j.jaad.2020.03.073] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Membrive Jiménez C, Pérez Ramírez C, Sánchez Martín A, Vieira Maroun S, Arias Santiago SA, Ramírez Tortosa MDC, Jiménez Morales A. Influence of Genetic Polymorphisms on Response to Biologics in Moderate-to-Severe Psoriasis. J Pers Med 2021;11:293. [PMID: 33921427 DOI: 10.3390/jpm11040293] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
2 Foss MG, Nyckowski T, Steffes W. Erythrodermic Psoriasis Exacerbated by Bupropion. Cureus 2021;13:e18460. [PMID: 34745784 DOI: 10.7759/cureus.18460] [Reference Citation Analysis]
3 Lo Y, Tsai TF. Updates on the Treatment of Erythrodermic Psoriasis. Psoriasis (Auckl) 2021;11:59-73. [PMID: 34136373 DOI: 10.2147/PTT.S288345] [Reference Citation Analysis]
4 Garces CC, Hernandez Garcilazo N, Sharma A, Nader G. Severe psoriasis presenting with rapidly progressive (crescentic) IgA-predominant glomerulonephritis. BMJ Case Rep 2021;14:e242627. [PMID: 34039551 DOI: 10.1136/bcr-2021-242627] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Megna M, Fabbrocini G, Ferrillo M, Cinelli E. Erythrodermic psoriasis successfully and rapidly treated with brodalumab: Report of two cases. Dermatol Ther 2020;33:e14351. [PMID: 32981222 DOI: 10.1111/dth.14351] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Ghamrawi RI, Ghiam N, Wu JJ. Comparison of psoriasis guidelines for use of IL-23 inhibitors in the United States and United Kingdom: a critical appraisal and comprehensive review. J Dermatolog Treat 2020;:1-5. [PMID: 32962478 DOI: 10.1080/09546634.2020.1826394] [Reference Citation Analysis]
7 Membrive Jiménez C, Pérez Ramírez C, Sánchez Martín A, Vieira Maroun S, Arias Santiago S, Ramírez Tortosa MC, Jiménez Morales A. Clinical Application of Pharmacogenetic Markers in the Treatment of Dermatologic Pathologies. Pharmaceuticals (Basel) 2021;14:905. [PMID: 34577605 DOI: 10.3390/ph14090905] [Reference Citation Analysis]
8 Liu LC, Jin XH, Sun C, Xia JX. Two cases of refractory erythrodermic psoriasis effectively treated with secukinumab and a review of the literature. Dermatol Ther 2021;34:e14825. [PMID: 33527631 DOI: 10.1111/dth.14825] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Gioe OA, Savoie C, Grieshaber EB, Hilton DC. Treatment of erythrodermic psoriasis with apremilast. JAAD Case Rep 2021;11:36-7. [PMID: 33898682 DOI: 10.1016/j.jdcr.2021.03.011] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Kanneganti A, Bhadiraju P, Tong PSY. Extragonadal teratomas in women and adolescent girls: A systematic review. Eur J Obstet Gynecol Reprod Biol 2021;262:134-41. [PMID: 34022590 DOI: 10.1016/j.ejogrb.2021.05.005] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Carriero M. Erythrodermic psoriasis and palmoplantar hyperkeratosis successfully treated with secukinumab: a case report. dti 2022;16:1-5. [DOI: 10.33393/dti.2022.2355] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Trovato E, Orsini C, Russo F, Cortonesi G, Rubegni P. Ixekizumab as treatment of erythrodermic psoriasis. Dermatol Ther 2021;34:e14868. [PMID: 33571383 DOI: 10.1111/dth.14868] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
13 Cretu S, Salavastru CM, Tiplica GS. Treatment of psoriatic erythroderma using systemic corticosteroids: A timeless option? Dermatol Ther 2020;33:e14222. [PMID: 32820848 DOI: 10.1111/dth.14222] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]